1. Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes
- Author
-
C H J, Lamers, S, Sleijfer, R A, Willemsen, R, Debets, W H J, Kruit, J W, Gratama, and G, Stoter
- Subjects
Clinical Trials as Topic ,Receptors, Antigen, T-Cell ,Antibodies, Monoclonal ,Cytotoxicity Tests, Immunologic ,Flow Cytometry ,Immunotherapy, Adoptive ,Transplantation, Autologous ,Xenograft Model Antitumor Assays ,Interferon-gamma ,Mice ,Treatment Outcome ,Liver ,Antigens, Neoplasm ,Transduction, Genetic ,Animals ,Humans ,Lymphocyte Count ,Carcinoma, Renal Cell ,Immunoglobulin Fragments ,T-Lymphocytes, Cytotoxic - Abstract
Adoptive transfer of antigen-specific T cells has recently shown therapeutic successes in the treatment of viral infections and tumors. T cells specific for the antigen of interest can be generated in vitro, and adoptively transferred back to provide patients with large numbers of immune-competent T cells. Adoptive T cell therapy, however, is a patient-tailored treatment that unfortunately is not universally applicable to treat viral infections and tumors. We and others have demonstrated that the transfer of genes encoding antigen-specific receptors into T cells (i.e., genetic retargeting) represents an attractive alternative to induce antigen-specific immunity. Currently, we evaluate this concept in a clinical protocol to treat patients with metastatic renal cell cancer (RCC) using autologous RCC-specific gene-modified T lymphocytes.
- Published
- 2004